Sort   by:  
 Page size 
TranscriptomicsProstate Cancer Gene Expression Changes with Neoadjuvant Hormone Therapy
Men with clinically localized prostate cancer were treated with 0 to 9 months of neoadjuvant hormone suppression prior to prostatectomy. Keywords: microarray, hormone, 9 men with prostate cancer were assigned to neoadjuvant hormone suppression therapy for 3-6, 6, or 0 months.
ORGANISM(S): Homo sapiens 
2008-12-01 | E-GEOD-9983 | biostudies-arrayexpress
TranscriptomicsIGR_CAP1_DOCETAXEL_GE_STUDY_AC
'Prostate cancer is the second cancer diagnosed among men worldwide. Beside approval of new therapies in the last five years, chemotherapeutic agents, docetaxel and cabazitaxel taxanes remain key treatments for metastatic castration resistant prostate cancers. However, primary and acquired resistanc...
ORGANISM(S): Homo sapiens 
2018-11-07 | E-MTAB-4869 | biostudies-arrayexpress
UnknownAbiraterone in metastatic prostate cancer without previous chemotherapy.
Not available
S-EPMC3683570 | biostudies-literature
UnknownGuidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Not available
S-EPMC4835977 | biostudies-literature
UnknownAdding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Not available
S-EPMC7616360 | biostudies-literature
UnknownDuration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Not available
S-EPMC7616389 | biostudies-literature
Sort   by:  
 Page size